Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus. by Kim, Byungji et al.
UC San Diego
UC San Diego Previously Published Works
Title
Immunogene therapy with fusogenic nanoparticles modulates macrophage response to 
Staphylococcus aureus.
Permalink
https://escholarship.org/uc/item/5mf9p45w
Journal
Nature communications, 9(1)
ISSN
2041-1723
Authors
Kim, Byungji
Pang, Hong-Bo
Kang, Jinyoung
et al.
Publication Date
2018-05-17
DOI
10.1038/s41467-018-04390-7
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE
Immunogene therapy with fusogenic nanoparticles
modulates macrophage response to Staphylococcus
aureus
Byungji Kim1, Hong-Bo Pang2,3, Jinyoung Kang4, Ji-Ho Park 5, Erkki Ruoslahti2,6 & Michael J. Sailor 1,4,7
The incidence of adverse effects and pathogen resistance encountered with small molecule
antibiotics is increasing. As such, there is mounting focus on immunogene therapy to aug-
ment the immune system’s response to infection and accelerate healing. A major obstacle to
in vivo gene delivery is that the primary uptake pathway, cellular endocytosis, results in
extracellular excretion and lysosomal degradation of genetic material. Here we show a
nanosystem that bypasses endocytosis and achieves potent gene knockdown efficacy. Porous
silicon nanoparticles containing an outer sheath of homing peptides and fusogenic liposome
selectively target macrophages and directly introduce an oligonucleotide payload into the
cytosol. Highly effective knockdown of the proinflammatory macrophage marker IRF5
enhances the clearance capability of macrophages and improves survival in a mouse model of
Staphyloccocus aureus pneumonia.
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Deep-tissue Staphyloccocus aureus infection is a majortherapeutic challenge. S. aureus is a Gram-positive bac-terium that predominantly infects the skin and the
respiratory system causing pneumonia; local infections can
become systemic in the most serious form of Staphylococcal
disease, sepsis1. At high levels of bacterial burden in the lungs,
Staphyloccocal pneumonia becomes fatal due to two major fac-
tors: (1) pathogenic activity by S. aureus and (2) prolonged
inflammation caused by the body’s immune system. The acute
inflammatory response at the site of an infection involves the
secretion of cytokines by alveolar macrophages, recruiting poly-
morphonuclear neutrophils (PMN) and monocytes from circu-
lation that differentiate into macrophages2. Alveolar
inflammation causes extensive bleeding and exudation that slow
down vascular flow and impede breathing2,3, and prolonged
excretion of inflammatory cytokines reduces the chances of
recovery3. Although the immediate inflammatory response to
Staphylococcal pneumonia is necessary for rapid elimination of
the threat, it must be balanced with inflammation suppression
and tissue repair to maintain lung homeostasis4.
Owing to toxic adverse effects of small molecule antibiotics
such as vancomycin5 and the emergence of strains resistant to
these therapeutics2 therapies are needed to activate the immune
system to treat bacterial infections6–9. Macrophages are a
potential target for such therapies owing to their polar functions
as inflammatory, immune stimulatory phagocytes M1 macro-
phages, or as anti-inflammatory phagocytic M2 macrophages
associated with bacterial phagocytosis and tissue repair func-
tions10–15. M1 macrophages are marked by the Irf5 gene, which
upregulates tumor necrosis factor (TNF), interleukin (IL)-1, IL-6,
IL-15, IL-18, and IL-23, and downregulates anti-inflammatory
cytokines such as IL-1010,12–15. Knockdown of Irf5 in the early
stages of Staphylococcal pneumonia can curtail prolonged
inflammation by preventing the excretion of inflammatory
cytokines, allowing the immune system to clear bacteria and
repair tissue10,15,16.
Despite much effort, in vivo knockdown of genes has still not
been of great success. Naked RNA has a short half-life in vivo;
thus, various types of nanoparticle (NP) delivery vehicles have
been used to protect the oligonucleotide and deliver it intra-
cellularly17–19. The most common means of delivery is with lipid
NPs20, which are readily endocytosed by the cell, leading to
extracellular excretion of 70% of the small interfering RNA
(siRNA) payload, with the remaining siRNA undergoing lysoso-
mal degradation. Typically, only 1–2% of administered siRNA
escapes early endosomal uptake to potentially undergo RNA
interference (RNAi)21–23. In order to increase the quantity of
RNA delivered, polymeric and related hybrid NPs have been
engineered with cationic polyethylenimine (PEI) components.
Although it increases the carrying capacity of the NPs, PEI is also
cytotoxic24,25. Some lipid constituents, such as dioleoylpho-
sphatidylethanolamine or 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), impart a fusogenic nature to liposomes that
enables them to fuse with the cellular membrane, mitigating
toxicity, and enhancing cellular delivery of genes26–29. With some
PEGylated lipid compositions, fusogenic liposomes have been
shown to bypass endocytosis altogether, much like the endo-
genous soluble N-ethylmaleimide-sensitive factor attachment
protein receptor (SNARE)-mediated vesicular uptake
mechanism30,31.
Although cellular penetration is important, gene therapeutics
must also reach the appropriate cell to be effective18,19,32–34. Here
we present a solution to these problems that uses NPs containing
a targeting peptide specific for activated macrophages and a
fusogenic liposomal coating (F-pSi). Membrane fusion enables
direct release of hydrophilic payloads from the core of NP directly
into the cell cytoplasm, the transfer of hydrophobic molecules
from the liposomal bilayer to the cell membrane bilayer, and the
transfer of moieties conjugated on the outer surface of the lipid
coat (including antibodies, small molecules, and peptides) to the
cell membrane. By avoiding endocytosis entirely, the fusogenic
coating increases the probability that siRNAs will reach the
perinuclear region to undergo RNAi. In addition, in place of
conventional peptide-based and polymeric NPs (such as prota-
mine, poly-L-lysine, and PEI), we use porous silicon NPs
(pSiNPs), which have been shown to be an effective gene delivery
vehicle35. The pSiNPs are prepared with a calcium silicate trap-
ping chemistry36 that can load and protect high quantities of
siRNA without the use of cytotoxic polymer stabilizers. We use
siRNA against Irf5 to inhibit the inflammatory phenotype of
macrophages and favor phagocytotic function. These
macrophage-targeting F-pSi hybrid NPs have high siRNA
knockdown efficiency in vitro and provide strong therapeutic
efficacy against a S. aureus infection in mice, affording full
recovery from a lethal dose. This study is the first successful
in vivo demonstration of gene silencing for immunotherapy of
deep-tissue infection, with implications for the treatment of
antibiotic-resistant bacterial infections.
Results
Synthesis of fusogenic lipid-coated pSiNPs. The siRNA carrier
consisted of pSiNPs, prepared by electrochemical etch of single-
crystal silicon wafers, and ultrasonic fracture of the resulting
porous layers into NPs. siRNA and hydrophilic fluorescent dye
payload were loaded into the porous NPs by subjecting the
payload and the pSiNPs to ultrasound in an aqueous solution of
calcium chloride36. Fusogenic liposomes were synthesized using
the established film hydration method30,31 and were coated
around the payload-loaded pSiNPs by co-extrusion through 200
nm polycarbonate membranes (Fig. 1b). The fusogenic (F) feature
of the liposomes is derived from a controlled ratio of structural,
cationic, and PEGylated lipid components30,31 (Supplementary
Table 1). Control non-fusogenic (NF) NPs were prepared using
the structural and PEGylated lipids, but without the cationic
component—yielding a more conventional liposome. Dynamic
light scattering (DLS) and microscopic data on the F-pSiNPs
confirmed an average hydrodynamic diameter of
~ 190 nm with a distribution range of 100–400 nm, with a
cationic surface charge of ~ 10 mV (Supplementary Table 2). The
F-pSi formulations were physically stable in deionized water for
up to 28 days at 4 °C (Supplementary Fig. 1). The loading effi-
ciency of the siRNA payload was ~ 25 wt%, substantially larger
than the 1–14 wt% achieved with other reported oligonucleotide-
loaded nanoplatforms, such as lipid-based NPs and mesoporous
Si-polymer hybrid systems (Supplementary Table 3). Notably,
particles with sizes comparable to those used in the present study
(200 nm) have displayed oligonucleotide loadings of < 5 wt%.
Intracellular delivery of fusogenic pSiNPs in vitro. NPs
were loaded with the hydrophilic dye calcein in the pSi core or
with the lipophilic dye 1,1’-dioctadecyl-3,3,3’,3’-tetra-
methylindocarbocyanine perchlorate (DiI) in the lipid leaflets to
evaluate differences in intracellular localization and to infer
uptake pathway. Calcein was chosen as the model-siRNA payload
(Fig. 2a), because it shares two key characteristics with oligonu-
cleotides: (i) it is anionic and (ii) it is membrane impermeable.
The lipophilic DiI was chosen to track fusogenic uptake, because
the hydrophobic molecule localizes in lipid bilayers (Fig. 2a)37. In
the event of fusogenic uptake, DiI would be expected to diffuse
from the liposomal bilayer of the NP into the plasma membrane,
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whereas NF uptake would result in endocytosis and localization
in the cytoplasm.
Confocal microscopy revealed that the F-pSi formulation fused
with the plasma membrane of cultured J774A.1 murine
macrophages and delivered the payload into the cytoplasm. The
F-pSi formulation that contained DiI in the liposomal coating
transferred this lipophilic dye to the cell membrane (Fig. 2b),
confirming fusion, whereas the F-pSi formulation that contained
calcein in the NP interior dispersed this hydrophilic dye
throughout the cytoplasm (Fig. 2c). Control experiments
performed using NF NPs resulted in an overall lower uptake
and the DiI signal from the NF formulation were found to be
concentrated within the cytoplasm (Fig. 2e). The fact that these
NPs were associated with intracellular endosomes/lysosomes was
confirmed using LysoTracker Red stain (Figs. 2c, 2f). By contrast,
fusogenic NPs showed dispersed calcein signals that did not co-
localize with lysosomal compartments. The F-pSiNPs attained an
average Pearson’s correlation coefficient (PCC)= 0.04 ± 0.03,
whereas the NF-pSiNPs attained an average PCC= 0.59 ± 0.18.
The two values are significantly different by T-test (p= 2 × 10−6),
validating the lysosomal compartmentalization of the NF-pSi
formulation.
The ability of the nanoparticles to be selectively targeted to
macrophages was tested using a peptide selected in a phage
library screen38,39 for cultured J774A.1 murine macrophages
(Supplementary Fig 2a). This peptide, denoted as CRV, is a nine-
amino acid peptide (sequence CRVLRSGSC) made cyclic by a
disulfide bond between the side chains of the two cysteine
residues. CRV labeled with a 5-FAM dye (FAM-CRV) showed
higher binding to J774A.1 and Raw 264.7 macrophages relative to
control peptides (Supplementary Fig. 2b). Biotin-labeled CRV
was able to significantly reduce the binding of FAM-CRV to the
macrophages (Supplementary Fig. 2c). All these results suggest
that CRV peptide specifically binds to macrophages.
To permit coupling to the NPs, the peptide was modified by
adding a third cysteine through a 6-aminohexanoic acid linker
and labeled with a 5-FAM dye in order to allow tracking by
fluorescence. The 3-cysteine peptide was attached to the
polyethylene glycol (PEG) head of a minor fraction of the lipids
via maleimide coupling chemistry. A fusogenic formulation
containing CRV, the DiI membrane dye, and pSiNPs (F-DiI-
CRV) showed strong colocalization of the DiI and FAM signals at
specific points on the cell membrane (Fig. 2d), suggesting that
CRV anchors the particles to its specific macrophage membrane
receptors to allow localized fusion. The data are more consistent
with a membrane fusion mechanism rather than endocytosis;
substantial endocytosis would be expected to lead to increased DiI
signals from the cell cytoplasm. We note that CRVs appeared to
expedite the fusion process, as only half the incubation time was
needed to achieve a comparable level of fusion. In contrast, the
NF-DiI-CRV construct (Fig. 2g) displayed a cellular distribution
similar to NF-DiI-mPEG, a NF formulation that contained mPEG
(methoxy PEG) in place of the targeting peptide-conjugated PEG
(Fig. 2e). The CRV-FAM and DiI signals colocalized in clusters
within the cytoplasm, indicative of endosomal and lysosomal
compartmentalization. These results indicate the targeting
peptide is permissive for either cell entry pathway.
Transmission electron microscope (TEM) results (Fig. 2h–j)
verify the different uptake pathways between fusogenic and NF
formulations. Although the targeted NF particles demonstrated
macropinocytosis, and were found to be localized in intracellular
vesicles (Fig. 2i), the pSi cores of the targeted fusogenic particles
were found degrading in the cell cytoplasm (Fig. 2j).
Biosafety and in vitro knockdown using fusogenic pSiNPs. To
test the hypothesis that the fusogenic pathway for uptake and
direct cytoplasmic release of siRNA attains higher knockdown
efficiency than the endosomal uptake route, we delivered siRNA
encoding the Irf5 gene to cultured Raw 264.7 macrophage cells
and gene expression was analyzed by quantitative real-time PCR
(qRT-PCR) (Fig. 3a). Fusogenic NP formulations (F-siIRF5)
delivering 200 nM siRNA demonstrated high knockdown effi-
ciencies with or without an added CRV macrophage-targeting
peptide (96.4% and 96.6%, respectively). Knockdown was com-
parable to that of the standard transfection agent, Lipofectamine
(95.5%). The NF formulation (NF-siIRF5-CRV) demonstrated
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Fig. 1 Fusogenic pSi nanoparticle system (F-pSi). a Schematic showing mode of action of the fusogenic pSiNP. b Schematic showing nanoparticle synthesis,
including (1) siRNA loading into the porous silicon nanoparticles and sealing by precipitation of calcium silicate; (2) coating of the nanoparticle clusters
with cationic liposome; and (3) conjugation of targeting peptides to the liposomal exterior. c TEM image of final F-pSi constructs, showing cloudy liposomal
coatings around dark and dense porous silicon-based cores. Imaged using JEOL 1200 EX TEM. Negative staining by 2% phosphotungstic acid. Scale bar
indicates 200 nm
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04390-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1969 | DOI: 10.1038/s41467-018-04390-7 |www.nature.com/naturecommunications 3
only 42.9% knockdown with high SD. The relatively high variance
in this control is attributed to occasional incidences of endosomal
escape22. Administration of free siIrf5 achieved only 6.3%
knockdown under similar conditions, statistically similar to the
phosphate-buffered saline (PBS) control. The presence of CRV
peptides on the particle surface had no adverse effect on knock-
down ability. These experiments established that the fusogenic
coatings enable higher knockdown efficiency than a conventional
liposomal coating, and that active targeting of the fusogenic
formulations does not enhance gene silencing in the isolated
cellular environment of the in vitro experiment, likely because the
long incubation period allowed the entry of non-targeted NP to
catch up with the targeted NPs.
Assays of cell cytotoxicity and histological evaluations of major
organs were performed to assess biosafety of the fusogenic NPs
and their siRNA payload. The primary concern with the
fusogenic system is the insertion of the cationic lipid constituents
into cell membranes, disrupting membrane charge homeostasis in
the cells. Two macrophage cell lines, J774a.1 and Raw 264.7, were
incubated for 1 h with NP formulations containing 0.5 and 1mg
total lipid mass. Calcein AM and ethidium homodimer-1 (EthD-
1) assays indicated > 95% cell viability compared with the PBS-
treated control for either fusogenic or NF CRV-targeted NP
constructs (Fig. 3b). To test in vivo biosafety, healthy Balb/C mice
were intravenously injected with the fusogenic, CRV-targeted NP
construct (F-siIRF5-CRV) at doses corresponding to 23.2 µmol/
kg lipid, corresponding to 24 µg/kg siRNA. After 24 h circulation,
the major organs were harvested and sectioned for hematoxylin
and eosin (H&E) histopathological evaluation (Fig. 3c–h). All
major organs were found to be normal, although the liver showed
minor incidental findings also seen in control mice.
Biodistribution and targeting of fusogenic pSiNPs. We estab-
lished a S. aureus pneumonia animal model involving intra-
tracheal injection of bacteria at a dose that was lethal to untreated
mice within 2 days. First, we tested the homing ability of the CRV
macrophage-targeting peptide in this model, using the “free”
peptide not bound to any NP, but conjugated to a fluorescein (5-
FAM) dye to allow tracking. Infected and healthy control mice (n
= 3 each) were intravenously injected with FAM-CRV 24 h post
infection. Confocal immunofluorescence microscopy of organs
collected from the healthy animals showed signs of renal clear-
ance but no selective homing to any of the macrophage-heavy
organs (Fig. 4a). However, the infected animals demonstrated
clear evidence of selective homing, with CRV-FAM signals
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Fig. 2 Fusion and intracellular delivery of Fusogenic particles in vitro. a Particle schematic. Calcein, anionic calcein fluorescent dye; CRV, macrophage-
targeting peptide; DiI, the hydrophobic carbocyanine membrane stain; FAM, fluorescein label attached to targeting peptide; PEG, polyethylene glycol; pSi,
porous Si nanoparticles. b–g Confocal microscope images of J771A.1 murine macrophage cells; b after 10 min incubation with DiI-loaded F-pSi
nanoparticles; c after 1 h incubation with Lysotracker Red and 10min incubation with calcein-loaded F-pSi nanoparticles; d after 5 min incubation with CRV-
FAM-conjugated, DiI-loaded F-pSi nanoparticles; e after 10 min incubation with DiI-loaded NF-pSi nanoparticles; f after 1 h incubation with Lysotracker Red
and 10min incubation with calcein-loaded NF-pSi nanoparticles; g after 5 min incubation with CRV-FAM-conjugated, DiI-loaded NF-pSi nanoparticles. Blue
is DAPI nuclear stain. h–j Transmission electron microscope (TEM) images of Raw 264.7 murine macrophage cells after 10min incubation with
nanoparticles. h Cells treated with PBS (phosphate-buffered saline) control show no signs of particles; i cells treated with nanoparticles containing a non-
fusogenic lipid coating, siRNA against transcription factor Irf5, and the macrophage-targeting peptide (NF-siIRF5-CRV) display evidence of pinocytotic
uptake (arrowhead). Inset shows particles localized in vesicles (endosome/lysosome); j cells treated with nanoparticles containing fusogenic lipid coating,
siRNA against transcription factor IRF5, and the macrophage-targeting peptide (F-siIRF5-CRV) become localized in the cell cytoplasm. Scale bar represents
20 µm
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colocalizing with the F4/80-AF555 macrophage signals in the
infected lungs. The peptides cleared primarily through the kid-
neys, with minor localizations seen in the spleen and liver. The
results demonstrate the ability of the CRV peptide to home to
macrophages in S. aureus-infected lungs.
Next, we tested the in vivo homing ability of the CRV when
attached to the fusogenic NPs. Mice were intravenously injected,
24 h post infection, with DiI-loaded F-siIRF5 NPs coated with
conjugated CRV peptide, and the in vivo biodistribution was
tracked by immunofluorescence microscopy of organs harvested
at 1 h and 24 h post treatment. The quantified DiI fluorescence
signal showed strong accumulation in the lungs after 1 h and it
was still detected 24 h post treatment (Fig. 4b and Supplementary
Fig. 3 shows the representative images of the organs). Control
experiments using the same NP construct but replacing the CRV-
conjugated PEG with methoxylated PEG (F-DiI-mPEG) showed
minimal accumulation in the lungs. The efficacy of lung homing
was quantified by fluorescence-activated cell sorting (FACS),
which showed that the CRV-conjugated fusogenic particles (F-
DiI-CRV) homed to infected lungs with high selectivity
(Supplementary Fig. 4). Although the free-CRV peptide showed
preferential clearance through the kidneys, the NPs showed no
elevated fluorescence over background autofluorescence signals in
the kidneys, and substantially increased clearance through the
liver. These results were similar for both the targeted and the
untargeted fusogenic NP constructs, in both healthy and infected
animals. The clearance data are consistent with the size
limitations displayed by the organs of mononuclear phagocytic
system; NPs < 5.5 nm tend to be cleared by the kidneys and NPs
show preferential clearance through the hepatobiliary system40,41.
We note the CRV-conjugated NPs showed substantially enhanced
uptake in the spleen of infected animals relative to controls,
which is attributed to the splenic clearance and filtration of
targeted macrophages that have phagocytosed senesced neutro-
phils and damaged cells from the infected lung.
We next studied the efficacy of CRV targeting and fusogenic
uptake at the cellular level in the lungs using DiI-tagged NPs. The
lungs of healthy mice intravenously injected with targeted
fusogenic NPs (F-DiI-CRV) showed minimal recruitment of
macrophages marked by F4/80-fluorescein isothiocyanate (FITC)
and no visible F-DiI-CRV accumulation (Fig. 4c). Healthy lungs
possess a baseline number of alveolar macrophages, with no
significant recruitment of peripheral macrophages. However, the
lungs of infected control mice (PBS injection at 24 h post
infection) recruited a high number of macrophages, as expected
of an inflammatory process (Fig. 4d). The group of infected mice
injected (24 h post infection) with NF NPs (NF-DiI-CRV)
showed minimal colocalization of macrophages with DiI from
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formulations (F-siIRF5-mPEG, F-siIRF5-CRV) and lipofectamine. *Significant difference (one-way ANOVA with Tukey’s HSD post hoc test, p-level < 0.05, F
(5, 30)= 28, p= 6.9 × 10−10). b Viability of J774a.1 and Raw 264.7 macrophage cells after 1 h incubation with NF-siIRF5-CRV and F-siIRF5-CRV
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these NPs (Fig. 4e). In marked contrast, infected lungs of mice
injected with the targeted fusogenic NPs (F-DiI-CRV) showed
high accumulation of DiI signals, which were strongly colocalized
with macrophage fluorescence signals (Fig. 4f). Taken together,
the results show that the combination of CRV targeting and
fusogenic uptake achieves strong homing to circulating macro-
phages recruited to infected lungs.
Therapeutic efficacy of targeted fusogenic pSiNPs. With the
cellular fusion and in vivo homing capabilities established, we
next evaluated the therapeutic efficacy of the fusogenic, siRNA-
loaded, CRV-targeted nanosystem (F-siIRF5-CRV) against a
lethal dose of S. aureus in the mouse pneumonia model. As
discussed above, we chose to deliver siRNA against the Irf5 gene
of macrophages, in order to suppress inflammatory cytokine
excretion of macrophages13 and enhance bacterial phagocytosis
and tissue repair10,15,16. We initially studied bacterial coloniza-
tion and titers in the lungs of mice in three treatment groups as
follows: (i) S. aureus-infected mice with no treatment (lungs
collected at fatality); (ii) infected mice treated with PBS (lungs
collected at fatality within 24 h post treatment); and (iii) infected
mice treated with F-siIRF5-CRV via tail vein injection (lungs
collected 3 days post treatment). A section of a healthy lung is
shown for comparison in Fig. 5a. The infected mice, when
untreated (Fig. 5b) or treated with PBS only (Fig. 5c), displayed
overt signs of neutrophilic pneumonia associated with bacteria.
Moreover, S. aureus leakage into the perilaryngeal muscles was
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mouse with no treatment (inset shows large population of S. aureus in the perilaryngeal muscle). c Lung of infected mouse ad mortem 24 h post-PBS
treatment (inset shows gram stain of S. aureus populations in the lung); d Lung of infected mouse treated with F-siIRF5-CRV nano-therapeutic
(administered at 23.2 µmol/kg lipid, 24 µg/kg siRNA, 0.5 mg/kg pSi) at 3 days post treatment (inset shows lower magnification of the same). e Bacterial
titer from lungs of healthy and infected mice injected with PBS, NF-siIRF5-CRV (non-fusogenic, targeted nanoparticle containing siIrf5 therapeutic), F-siLuc-
CRV (fusogenic, targeted nanoparticle containing siRNA against luciferase, as a negative control for siIrf5), and F-siIRF5-CRV (fusogenic, targeted
nanoparticle containing siIrf5 therapeutic). Animals were infected on day 0 and therapeutic or control injections were given on day 1. The dashed red line
indicates the average count of colony-forming units (CFU) in healthy mouse lungs. Error bars indicate SD. Each bar represents n= 8 animals. *Ad mortem;
no measurements due to death of all mice in the cohort. f Mouse survival post-infection (at day 0) and post-therapeutic injection (at day 1) of PBS, NF-
siIRF5-CRV, F-siLuc-CRV, or F-siIRF5-CRV. Each group has n= 8 mice. g Average days of survival of mice from f post-infection and post-therapeutic
injection. One-way ANOVA with Tukey’s HSD post hoc test (p-level < 0.05, F (3, 28)= 17, p= 1.77 × 10−6) revealed significant difference between F-
siIRF5-CRV therapeutic and remaining three groups (PBS, NF-siIRF5-CRV, and F-siLuc-CRV). All animal experiments were performed independent of each
other with different cohorts of mice
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observed in these untreated controls (Fig. 5b, inset), and Gram-
positive cocci were identified in the lungs of the PBS-injected
group by Gram staining (Fig. 5c inset). Three days after injection
of the F-siIRF5-CRV therapeutic, the lungs of the infected mice
displayed an appearance similar to healthy lungs and no bacteria
were detected in the Gram stains (Fig. 5d).
We also quantified the bacterial population in the various
treatment groups by preparing lung homogenates and counting
the number of bacterial colonies obtained (Fig. 5e). Healthy mice
showed an average baseline count of ~ 103 colony-forming unit
(CFU)/g. Control groups of infected mice treated with PBS, with
the NF targeted NP formulation containing siIrf5 (NF-siIRF5-
CRV), or with the fusogenic targeted NP containing siRNA
against luciferase as a negative control for siIrf5 (F-siLuc-CRV),
were all observed to carry bacterial burdens of > 1010 CFU/g and
all cohorts perished within 3 days of infection. By contrast,
infected mice treated with the fusogenic targeted NP delivering
the siIrf5 therapeutic (F-siIRF5-CRV) demonstrated a notable
decrease in titer starting 2 days post infection and titers reached
the baseline count at 8 days post infection.
To confirm that the therapeutic effect resulted from Irf5
knockdown, qRT-PCR was used to determine the relative in vivo
knockdown efficiency in infected mice. Bronchoalveolar lavage
(BAL) fluid collected from the lungs of infected mice was
observed to have significantly lower expression of Irf5 (17%) in
mice injected with the CRV-conjugated fusogenic pSiNPs relative
to the PBS, free siIrf5, CRV-conjugated NF-pSiNPs, and non-
targeted fusogenic pSiNP controls (Supplementary Fig. 5a).
However, the lung homogenates processed after removal of
BAL fluid showed no significant difference in Irf5 expression
between all groups (Supplementary Fig. 5b). BAL fluid in healthy
mice consists of 98% macrophages42, whereas infected mouse
BAL fluid accumulates activated macrophages and neutrophils
that are recruited during the initial stages of inflammation; by
seven days post infection, the BAL fluid comprises 38%
macrophages, 56% neutrophils, and 6% lymphocytes42. As the
BAL fluid was collected 48 h post infection and 24 h post-
therapeutic injection, the population is expected to be primarily
macrophages. On the other hand, the lung homogenate is
composed of epithelial, endothelial, and interstitial cells43, with a
small population of macrophages. Thus, we conclude that the
CRV-conjugated fusogenic particles successfully homed to the
activated macrophages of the infected lungs in a selective manner
and silenced Irf5 gene expression.
In a separate experiment, mouse survival was dramatically
improved with the F-siIRF5-CRV nano-therapeutic; 100% of the
mice administered the formulation survived the lethal challenge
and showed no apparent sequelae from the infection within a 4-
day post-infection observation period (Fig. 5f). Mice administered
the NF-siIRF5-CRV, and mice administered the F-siLuc-CRV,
with siLuc as a sham siRNA, showed limited survival, with a
significantly lower average number of survival days compared
with the F-siIRF5-CRV (one-way analysis of variance (ANOVA),
post hoc comparisons using Tukey’s honest significant difference
(HSD) test, Fig. 5g). By comparison, the first-line antibiotic
vancomycin gave only 30% survival rate in the same pneumonia
model when intravenously administered at a 3 mg/kg (the
published ED50 for vancomycin in mice is in the range 0.65–4
mg/kg44,45) single dose given one day post infection46.
Discussion
A primary role of the inflammatory response during bacterial
infection is to recruit additional macrophages whose function
ultimately shifts to bacterial phagocytosis and tissue repair10–15.
However, an excessive inflammatory reaction can become septic,
generating multi-organ failure and fatality2,3. This study har-
nessed siRNA targeting the Irf5 gene, a transcriptional regulator
of the inflammatory M1 macrophage phenotype that is a key
inductor of proinflammatory cytokines11. We hypothesized that
effective silencing of this gene would suppress the inflammatory
response and mitigate a lethal bacterial infection.
Silencing of Irf5 has not previously been tested as a means to
slow or eliminate bacterial infections. A serious bacterial infec-
tion, such as the lethal S. aureus model studied here, requires an
overwhelming and effective immune response. Although Irf5 is an
attractive target, it was not clear that a strong response could be
achieved using gene therapy alone, which can be notoriously
inefficient in vivo47. Achieving high in vivo knockdown efficiency
has been a challenge due to passive clearance in circulation and
endocytic uptake that causes extracellular excretion or lysosomal
degradation of the oligonucleotides22,23. In this work, we
addressed these problems by incorporating three key features into
the NP design: (i) a host pSiNP with high oligonucleotide loading
efficiency and low systemic toxicity; (ii) a fusogenic lipid coating
that effectively avoids endosomal uptake; and (iii) a targeting
peptide that selectively homes the NPs to macrophages.
The first new aspect of the present approach was the NP host
for the RNAi therapeutic. The carrier was based on porous sili-
con, a drug delivery vehicle that has shown good biocompat-
ibility48–50, and an ability to load and protect sensitive
therapeutics, such as proteins51–53 and oligonucleotides35,54,55.
We used a self-sealing chemistry that trapped the oligonucleotide
payload within the NP in a calcium silicate matrix36, loading a
quantity at least 2 × greater than has been achieved with typical
liposomal or related hybrid carriers (Supplementary Table 3). The
calcium silicate pSiNPs follow the preparation protocol as
introduced in Kang et al.36 In brief, large quantities of siRNA are
loaded into pSi by precipitating a calcium silicate shell that
simultaneously traps the payload. As the pSi matrix dissolves, the
silicate product reacts with calcium (II) ion present in the CaCl2
solvent, and forms Ca2SiO4 at the NP surface. To load siRNA, the
oligonucleotide is added to the solvent to trap the molecules
during the Ca2SiO4 shell formation. Between the presented work
and the referenced formulation, the pSi chemistry and properties
were identical, with the exception of particle size (which was ~
180 nm36). Thus, the pore volume in the F-pSi system is also
expected to decrease by ~ 80% (1.36 ± 0.03 to 0.29 ± 0.04 cm3 g
−1) upon shell formation. In contrast to the referenced work, the
small pSiNP sizes (68.1 ± 5.8 nm; Supplementary Table 2) in the
F-pSi system allows it to dissolve at an accelerated rate under
physiological conditions (pH 7.4, 37 °C). Moreover, the higher
mass loading is important in minimizing the injected dose and
maximizing gene silencing in the cells. Also, unlike the cationic
polymer or oligomer stabilizers usually employed to increase
loading of negatively charged oligonucleotide payloads, Ca2+ is
an endogenous species that is essential for cellular function.
Second, we introduced a liposomal coating that protected the
NP from premature degradation until cellular fusion. The coating
contained a specific composition of lipids that favored fusion with
the cellular membrane over endocytosis (Fig. 2b–g). The fuso-
genic lipid coating was composed of pro-fusogenic lipids and
moieties. 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC)
is the major constituent that acts as the structural backbone of the
liposome, with a relatively low phase transition temperature (Tm
= 24 °C). The low transition temperature gives the Lα liquid
crystal phase at room temperature and at body temperature56.
The Lα phase is the more fluidic, dynamic, and permeable
structure that allows for a wide size range (100–400 nm) of
extruded liposomal coatings and an easier fusion potential57.
DOTAP is the cationic lipid essential for the electrostatic
attraction toward the anionic plasma membrane58,59. Lastly,
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PEGylated lipid was also found to be imperative in fusion31;
although the exact mechanistic role of PEG is not yet known, it is
hypothesized that PEG binds water molecules to dehydrate the
lipid head groups, which leads to structural asymmetry in the
lipid alignment and drives double-leaflet to single-leaflet fusion as
the energetically favorable route60, similar to how SNARE pro-
teins anchor and pull vesicles into merging with plasma mem-
branes endogenously; in fact, neuronal SNAREs have been
observed to promote PEG-mediated fusion61. The fusion pathway
peeled off the protective liposomal coating, which enhanced the
rate of dissolution of the pSi carrier and release of the RNA
payload after the bare NP was inserted into the cytosol, giving
substantially greater knockdown of Irf5 in vitro (Fig. 3a).
Third, we used an activated macrophage-specific targeting
peptide, which provided strong and selective homing to macro-
phages in infected lungs. The effectiveness of the targeting peptide
in enhancing gene silencing was not apparent in vitro due to the
high efficacy of the fusogenic coatings (Fig. 3a). However, the
targeting peptide was critical for effective homing to macrophages
in infected lungs in vivo. The CRV-targeted NP constructs
localized in infected and not healthy lungs (Fig. 4b, c, f), whereas
NPs containing the sham targeting group showed little accumu-
lation in either infected or healthy lungs (Fig. 4b). Furthermore,
the CRV-conjugated NPs strongly colocalized with macrophages
in infected lungs (Fig. 4f).
The siRNA therapeutic chosen for this study focused on
enhancing the macrophage response to an infection by selectively
inhibiting a gene associated with inflammatory M1 macrophages.
Macrophages are essential components of the innate immune
system that are responsible for defense against a wide range of
pathogens. On a cellular level, the alveolar macrophages respond
to a challenge of infectious particles by secreting cytokines,
including TNF, IL-1β, IL-6, IL-8, IL-12, and IL-23 to recruit
PMNs, which secrete additional cytokines. However, this pro-
longed excretion of inflammatory cytokines results in deleterious
effects that drastically lower the chances of recovery62. In this
study, we knock down Irf5, a key proinflammatory marker of M1
inflammatory macrophages11.
There are two leading hypotheses regarding the role of Irf5 in
macrophages. The first is that knockdown of Irf5 in the M1
macrophage preserves its polarization, but eliminates proin-
flammatory factors12. It is known that knockdown of Irf5 inhibits
the expression of TNF and other inflammatory markers of M1
(e.g., IL12A and IL23A11), lowering recruitment of Th1/Th17 and
impeding inflammation. In addition, a decrease in the TLR-
mediated induction of proinflammatory cytokines (including IL-
6) leads to further decrease in inflammation63. The result of
eliminating the action of Irf5 is an overall reduction in extended
and damaging inflammation that occurs after initial leukocyte
recruitment, preventing destruction of lung infrastructure and
decreasing survival burden.
The second hypothesis is that Irf5 knockdown causes M1
macrophages to repolarize to the M2 phenotype and become
highly anti-inflammatory, yet strongly tissue-restorative10. In the
M2 phenotype, IL-10 is upregulated and IL-12 is downregulated,
the combination of which increases arginase-1 production to
reduce nitrogen monoxide excretion and inflammation10. More-
over, the M2 macrophages are known to induce Th2 cytokine
responses to mediate immune responses against extracellular
bacteria and toxins64. Thus, in the re-polarization model,
knockdown of IRF5 induces both anti-inflammatory tissue
regeneration and immune effects to reduce infection burden and
inhibit sepsis. Either model supports the hypothesis that knock-
down of Irf5 will improve healing of infections that induce an
excessive inflammatory response. Indeed, in vivo silencing of Irf5
has been shown to reduce inflammation and accelerate tissue
regeneration in mouse models of myocardial infarct and skin
wounds10. The improved healing response was attributed to
attenuation of M1 macrophage polarization, which is typically the
dominant macrophage phenotype in wounds shortly after injury.
In these prior studies, the siRNA was delivered in a lipidoidal NP
vehicle65.
Finally, it should be pointed out that the substantially
improved survival afforded by the targeted gene nano-therapeutic
developed in this work relative to a standardized dose of vanco-
mycin represents a significant finding. Vancomycin is a first-line
antibiotic, which is prescribed at high dosage and prolonged
administration when used to treat S. aureus infections5. S. aureus
strains have a history of evolving antibiotic-resistance genes, such
that we are currently facing vancomycin-intermediate and
-resistant strains that build strong peptidoglycan walls to bind
and trap vancomycin, and inhibit its therapeutic action2. The Irf5
knockdown approach used here is unlikely to be susceptible to
development of resistance.
Taken together, the combination of high payload capacity,
fusogenic uptake, and macrophage-specific targeting yielded an
Irf5-silencing construct that rescued all mice tested from a lethal
dose of S. aureus, and that gave the immune system time to clear
the bacteria and return the lungs of the infected animals to their
normal, healthy state within 7 days. The work reported here
represents the first example of successful immunogene therapy
against fatal deep-tissue infection. As the therapy focuses on
changing the host macrophage response to suppress excessive
inflammatory stimuli and enhance the antibacterial macrophage
activity through Irf5 silencing, rather than attacking a phenotypic
characteristic of the pathogen, the approach should be applicable
to a wide range of infections.
Methods
Materials. Highly boron-doped p-type silicon wafers (∼ 1 mΩ-cm resistivity,
polished on the (100) face) were obtained from Virginia Semiconductor, Inc or
Siltronix, Inc. Hydrofluoric acid (HF, 48% aqueous, ACS grade) was obtained from
Fisher Scientific. Anhydrous calcium chloride was obtained from Spectrum Che-
micals (Gardena, CA). Deionized (18 mΩ) water was used for all aqueous dilutions.
For lipids, DMPC, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(PEG)-2000], 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide
(PEG)-2000], and DOTAP were purchased from Avanti Polar Lipids (Alabaster,
AL) and stored at − 4 °C. Fluorescent dyes Calcein (Sigma-Aldrich) and hydro-
phobic DiI (Life Technologies) were used and Lipofectamine® 2000 Transfection
Reagent was obtained from Thermo Fisher Scientific. Custom siRNAs were pur-
chased from Dharmacon (Lafayette, CO) and primers were purchased from IDT
DNA (San Diego, CA). Macrophage-targeting peptide (CRV) was identified by Dr
Erkki Ruoslahti’s group at Sanford Burnham Prebys Medical Discovery Center
(SBPMDI, CA) and custom synthesized by CTC Scientific (Sunnyvale, CA). For
in vitro studies, Raw 264.7 and J774a.1 cells were purchased from ATCC (Mana-
ssas, VA) within 6 months before all experiments. Dulbecco’s modified Eagle’s
medium (DMEM) was purchased from GE Healthcare Life Sciences (HyClone,
Pittsburg, PA), with supplemental fetal bovine serum (HyClone) and penicillin/
streptomycin (HyClone). S. aureus subsp. aureus Rosenbach (ATCC® 25923™) was
purchased from ATCC within 6 months before all experiments, and 6-week-old
male Balb/C were purchased from Envigo (Placentia, CA).
Animals. Six- to 8-week old mice (BALB/C, male) were purchased from Envigo
(Indianapolis, IN). All animal experiments were performed independent of each
other with different cohorts of mice. All animals for the in vivo studies were
handled, anesthetized, and killed according to the Institutional Animal Care and
Use Committee (IACUC) guidelines, and all experiments followed the approved
protocol by the IACUC at SBPMDI.
Preparation of pSiNPs. pSi samples were prepared by electrochemical etching of
silicon wafers in an electrolyte consisting of 3:1 (v:v) of 48% aqueous HF:ethanol
(caution: HF is highly toxic and proper care should be exerted to avoid contact with
skin or lungs). A silicon working electrode with an exposed area of 8.6 cm2 was
contacted on the back side with aluminum foil and mounted in a Teflon cell. The
silicon wafer was then anodized in a two-electrode configuration with a platinum
counter electrode, by applying an alternating current of square waveform, with
lower current density of 50 mA/cm2 for 0.6 s and high current density of 400 mA/
cm2 for 0.36 s repeated for 500 cycles. Then the porous layer was lifted off by
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etching at a constant current density of 3.7 mA/cm2 for 250 s in a 1:20 (v:v) of 48%
aqueous HF:ethanol solution, to be sonicated in deionized water for 12 h into NPs.
Fluorescent dye and siRNA payloads were loaded into the pSiNPs by pore sealing
by calcium silicate formation; the calcium silicate sealing chemistry has demon-
strated high efficiency in loading anionic payloads previously36. Calcein was dis-
solved in PBS at 100 mM. One hundred and fifty microliters of calcein was pipetted
gently with 150 μl of pSiNP and 700 μl of 3 M calcium chloride under ultra-
sonication for 15 min. For siRNA loading, we used siIrf5 (Irf5, sense 5′-dTdT-CUG
CAG AGA AUA ACC CUG A-dTdT-3′ and antisense 5′-dTdT UCA GGG UUA
UUC UCU GCA G dTdT-3′), and siLuc (luciferase, 5′-CUU ACG CUG AGU
ACU UCG A-dTdT-3′ and antisense 5′-UCG AAG UAC UCA GCG UAA G
dTdT-3′). siRNA was dissolved in RNAse-free water to 150 µM and loaded into pSi
at the same volume ratio and process as calcein loading with only RNAse-free
water used as solvent.
Liposomal coating. Fusogenic coating (F) and NF coating were prepared from
DMPC, DSPE-PEG, and DOTAP at the molar ratio of 76.2:3.8:20 and 96.2:3.8:0,
respectively. The lipid films were prepared by evaporating the organic solvent, with
725.5 μg of DMPC, 151.6 μg of DSPE-PEG (methoxy or maleimide terminated),
and 196.3 μg of DOTAP (F) or 916.0 μg of DMPC and 151.6 μg of DSPE-PEG
(methoxy or maleimide terminated) (NF). The DiI-incorporated films were added
with 26.3 μg of DiI (1.25 mg/ml in 100% ethanol). The films were then hydrated
with payload-pSi solution and prepared by film hydration/extrusion; the pSi-
hydrated lipid was heated to 40 °C with constant magnetic stirring for 10 min.
Then the mixture was extruded through 200 nm polycarbonate membrane 20
times. CRV was conjugated to maleimide-terminated PEG by mixing 100 μl of 1
mg/ml CRV (in deionized water) in 1 mg/ml of the liposomal pSi (by lipid mass)
overnight at 4 °C. Particles were washed three times at each step by centrifugation
in Microcon-30 kDa Centrifugal Filter Unit (EMD Millipore) by spinning at
5000 × g at 25 °C. The loaded siRNA concentration was quantified by NanoDrop
2000 spectrophotometer (Thermo Fisher Scientific, ND-2000) after each step of
particle formation by checking the ultraviolet absorption of the supernatant and
pellet of each wash. NP size and zeta-potential were measured by DLS (Zetasizer
ZS90, Malvern Instruments), and structural morphology were visualized by JEOL
1200 EX II TEM and FEI Tecnai Spirit G2 BioTWIN TEM. Samples were prepared
by dropping 5 μl of the sample on the TEM grid, drying off excess solvent after 1
min, and dropping 5 μl of uranyl acetate for negative staining. Particle physiost-
ability was observed by storing the formulations in PBS, refrigerated at 4 °C and
measuring the hydrodynamic diameter every day for the first week, then every
7 days for a total of 4 weeks. The experiment was replicated three times and
averaged.
Macrophage-targeting peptide identification. Phage display screening was car-
ried out as previously described54. Briefly, the macrophage cell line used here was
J774A.1, a mouse monocyte/macrophage cell line isolated from ascites of female
animals bearing reticulum cell sarcoma. A T7 phage library displaying 9-residue
cyclic peptides (CX7C, two terminal Cysteine residues form a disulfide bond to
render peptide cyclic; X being random amino acid) was used for screening.
J774A.1 cells (2.5 × 105) were first incubated with 5 × 1010 pfu (plaque-forming
unit) inactivated phages displaying the sequence, RPARPAR, for 1 h at 4 °C.
RPARPAR is a prototypic CendR (C-end Rule) peptide that will bind to a known
receptor, neuropilin-1 (NRP1)55. Here, RPARPAR phages were inactivated for
their infection ability by UV exposure before incubation with cells, and the pre-
incubation of RPARPAR phage was to exclude all NRP1-binding peptide
sequences. Next, 5 × 109 pfu CX7C library was incubated with cells for another
hour at 4 °C. Phage titering and subsequent rounds of enrichment were carried out
according to our established protocol54. After three rounds of biopannings, the
peptide sequences between two terminal Cysteine were determined using next
generation sequencing performed by the DNA analysis core facility at SBPMDI.
Peptide binding to cells. FAM-X-CRV (X being one copy of 6-aminohexanoic
acid linker) and biotin-X-CRV were synthesized by Lifetein, LLC (Hillsborough,
NJ). The control peptides used here included GGSGGSKG and ARA peptide36.
Cells were incubated on rotator with indicated peptides at a final concentration of
10 µM in the solution of DMEM plus 1% bovine serum albumin. For competition
study, biotin-X-CRV was added to a final concentration of 500 µM together with
FAM-X-CRV (10 µM final). After 1 h at 4 °C, cells were washed three times with
PBS followed by flow cytometry analysis.
Affinity chromatography. The membrane proteins of Raw 264.7 cells were iso-
lated using Mem-PER Plus membrane protein extraction kit (Thermo Fisher Sci-
entific) according to the manufacturer’s instruction. Affinity chromatography was
then performed with a protocol adapted from our previous report54. Briefly, biotin-
X-CRV was first immobilized onto streptavidin coated magnetic beads (Thermo
Fisher Scientific), then incubated with the membrane protein extracts of Raw 264.7
cells at 4 °C overnight. After two times of washing with PBS, beads were first
incubated with 5′-GGSGGSKG-3′ peptide (a final concentration of 1 mM) at 4 °C
for 3 h, to elute those nonspecifically bound proteins. Lastly, beads were incubated
twice with FAM-CRV (a final concentration of 2 mM) at 4 °C (2 h each time), to
elute those proteins specially bound to CRV. The elutes from 5′-GGSGGSKG-3′
(control peptide) and FAM-CRV were collected and subjected to mass spectro-
metry analysis by the mass spectrometry core facility at SBPMDI.
Bacterial culture. All bacterial work was performed in an approved BSL-2 facility
with a clean hood. S. aureus was cultured by incubating 50 μl of bacteria in 10 ml of
the brain heart infusion broth (Fisher Scientific) for 16 h in a shaking incubator at
37 °C and shaking at 200 r.p.m. with the cap loose. The culture was re-introduced
to the lag phase from the stationary phase by sub-culturing 10 μl of bacteria in fresh
5 ml of brain heart infusion broth for 2 h in a shaking incubator at 37 °C and
shaking at 200 r.p.m. with the cap loose.
Cell culture. Raw 264.7 and J774a.1 macrophage cell lines were cultured in DMEM
supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were incu-
bated at 37 °C in 5% CO2.
Fusion of DiI-loaded or calcein-loaded nanoformulations were tested by seeding
6-well plates with 0.3 × 106 cells on top of 22 mm round coverslips (BD Biocoat
Collagen Coverslip, 22 mm), growing to 80% confluence overnight, and treating the
cells with the NPs at 1 mg lipid dose. The formulations without CRV conjugations
were incubated at 37℃ in 5% CO2 for 10 min, whereas the formulations with CRV
conjugation were incubated for 5 min. Calcein-loaded particles were incubated for
10 min after cells were pre-treated with 500 nM of LysoTracker Red DND-99
(Thermo Fisher Scientific) for 1 h at 37 °C in 5% CO2. The NF particles generally
demonstrate higher uptake (~ 3 ×) into cells relative to the fusogenic particles. For
clearer visualization of the LysoTracker, the dose of F-pSi-Cal NF-pSi-Cal was
decreased to 0.3 mg lipid dose. After incubation, the cells were washed in PBS three
times to remove any particles that were not taken up. The cells were fixed in 1%
paraformaldehyde (PFA, Santa Cruz Biotechnology) for 10 min, then washed with
PBS three times. The coverslips were mounted on glass slides with ProLong®
Diamond Antifade Mountant with DAPI (4',6-diamidino-2-phenylindole) (Life
Technologies), dried and kept in the dark until examined by confocal microscopy
(Zeiss LSM 710 NLO). PCC for colocalization was calculated using the Coloc2
plugin from ImageJ. At least ten representative images were analyzed to obtain the
average coefficient.
For TEM of cells, particles were introduced to the Raw 264.7 and J774a.1 cells
under the same conditions as above, and cells were fixed with glutaraldehyde
overnight before being stained with osmium and uranyl acetate during embedding,
and with lead on the TEM grids. The samples were viewed using a JEOL 1200 EX II
TEM instrument.
In vitro knockdown. In vitro knockdown efficiencies of the nanoformulations were
quantified using two-step qRT-PCR (Roche LightCycler 96). Raw 264.7 cells were
seeded on a six-well plate at 3 × 105 cells per well and grown to 80% confluency
overnight. The cells were incubated with the desired nanoformulations at 0.2 nmol
of siRNA in 2 ml of media (100 nM siRNA). Forty-eight hours post incubation, the
cell media was removed, and RNA was purified using the QIAshredder and RNeasy
Mini Kit (Qiagen, Valencia, Ca). cDNA was transcribed from the purified RNA
using the BIORAD iScript cDNA Synthesis Kit and heat-treated in the Eppendorf
Vapo.protect Mastercycler thermal cycler. cDNA was mixed with Irf5 primers, or
the control hypoxanthine phosphoribosyltransferase (HPRT) primers (Irf5 for-
ward: 5′-AATACCCCACCACCTTTTG-3′; Irf5 reverse: 5′-TTGAGATCCGGG
TTTGAGAT-3′; HPRT forward: 5′-GTCAACGGGGGACATAAAAG-3′; HPRT
reverse: 5′-CAACAATCAAGACATT-CTTTCCA-3′) and iQ SYBR Green Super-
mix according to the manufacturer’s instructions. RT-PCR analysis was performed
in the BIORAD 96-well white Multiplate PCR Plates using the Roche LightCycler
96. The quantification was performed at n= 6 and in RNAse- and DNAse-free
laminar flow hood dedicated to RNA work. Relative knockdown was statistically
evaluated using one-way ANOVA with Tukey’s HSD post hoc analysis.
Cell viability assay. Raw 264.7 and J774a.1 macrophages were cultured in six-well
plates on top of 22 mm round coverslips (BD Biocoat) to 80% confluency from
seeding density of 3 × 105 cells/well. The cells were incubated for 1 h with NP
formulations containing 0.5 mg and 1mg total lipid mass. After incubation, cells
were washed three times with PBS. Molecular Probes LIVE/DEAD Cell Viability/
Cytotoxicity Kit (Thermo Fisher Scientific) uses calcein AM for live cell uptake
(λex/λem= 494/517 nm) and EthD-1 for dead cell infiltration (λex/λem= 528/617
nm). The probes were treated and incubated with cells according to the manu-
facturer’s instructions. Briefly, probe stock was composed of 60 μl of 2 mM EthD-1
and 15 μl of 4 mM calcein AM in 30 ml fresh DMEM, and each cell well was
incubated with 2 ml of the probe stock for 30 min at room temperature in the dark.
The cells were then washed with PBS three times, fixed with 1% PFA, and mounted
on glass slides. The slides were dried and imaged using confocal microscopy (Zeiss
LSM 710 NLO) and the calcein AM/EthD-1 fluorescence signals were quantified
using ImageJ at n= 20. The cell viability was statistically evaluated using one-way
ANOVA. For fluorescence plate reader validation, the same experiment was con-
ducted in a 96-well plate with seeding density of 6000 cells/well in 200 μl media and
probe treatment. After 30 min room-temperature incubation in the dark, the
fluorescence was read in a Gemini XPS spectrofluorometer (Molecular Devices) at
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n= 8 per group. The quantified viability was normalized to the PBS control
treatment.
Biosafety of fusogenic NPs. For in vivo biosafety validation, healthy Balb/C mice
were intravenously injected with F-sIRF5-CRV at 23.2 µmol/kg lipid, corre-
sponding to 69 µg/kg siRNA, and 0.3 mg/kg pSi in 100 μl PBS. After 24 h circu-
lation, the mice were killed under deep isofluorane anesthesia (no response to toe
pinch) by cardiac perfusion, and the brain, heart, lungs, liver, kidneys, and spleen
were collected. Organs were fixed immediately in 4% PFA and sent to the Uni-
versity of California, San Diego (UCSD)’s histology core to be paraffinized and
sectioned for H&E staining. The stained slides were histopathologically evaluated
by Dr Kent Osborn (Associate Director, Animal Care Program, UCSD).
In vivo infection model. After 16 h incubation in brain heart infusion broth, 10 μl
S. aureus was sub-cultured in 5 ml of fresh broth for 2 h to reach growth phase. The
optical density at 600 nm was measured using a cuvette spectrometer with the
broth set as the blank. Five milliliters of bacterial culture at OD600 ≈ 0.32 was
centrifuged, the bacteria were washed by centrifugation in PBS three times, and re-
suspended in 200 μl of PBS for inoculation. The S. aureus pneumonia animal
model was established in 6- to 8-week-old male Balb/C mice by intratracheal
catheter injection of ~ 1 × 107 CFU of bacteria in 10 μl of PBS. All treatment
injections were performed 24 h after inoculation of the bacteria.
Biodistribution of CRV. Three healthy and infected (24 h post infection) mice
were intravenously injected with CRV tagged with 5’6-FAM dye in 100 μl PBS at a
concentration of 1 mg/ml. Organs were harvested after 1 h circulation and fixed in
4% PFA. Organs were sent to the UCSD histology core to be paraffinized, sec-
tioned, and stained with DAPI nuclei stain and F4/80-AF555 macrophage marker
for immunofluorescence analysis under the Zeiss LSM 710 NLO confocal micro-
scope with single photon laser (for excitation of DiI, calcein, LysoTracker Red) and
Mai-Tai Laser HB (690-1020 nm) (for two-photon excitation of DAPI).
NP biodistribution. Eight-week-old male Balb/C mice were intratracheally infected
as described. Twenty-four hours post infection, infected and healthy mice were
intravenously injected with siIrf5-loaded fusogenic pSiNPs with or without CRV
conjugation, at 23.2 µmol/kg lipid, corresponding to ~ 69 µg/kg siRNA, and 0.3 mg/
kg pSi 100 μl in PBS. The DiI-loaded particle localization was visualized using the
IVIS 200 (Perkin Elmer) with 0.12 s exposure time on the DsRed excitation and
emission filters. Both healthy and infected animals were killed and collected for
organs 24 h post infection, with additional 1 h post-treatment analyses for infected
animals injected with the fusogenic NP formulations. ImageJ was used to quantify
the fluorescence of each organ, and averaged over the three mice per group.
Infected lung homing was further validated using FACS. Twenty-four hours post
infection, mice were intravenously injected with calcein-loaded NF particles with
CRV, fusogenic particles without CRV, and fusogenic particles with CRV at 23.2
µmol/kg lipid, corresponding to 69 µg/kg siRNA, and 0.3 mg/kg pSi in 100 μl PBS.
One hour post injection, the mice were killed by cardiac perfusion with PBS. The
collected lungs were homogenized and the homogenates were processed with the
LSR Fortessa FACS instrument, and analyzed using the FlowJo software (FlowJo,
LLC). For immunofluoresce microscopy of infected lungs, mice were intravenously
injected 24 h post infection with DiI-loaded formulations of NF and fusogenic
particles (without siRNA) conjugated with CRV, and were killed for lung collection
and fixation in 4% PFA at 24 h post injection. The fixed lungs were paraffinized
and sectioned, and stained with FITC-labelled F4/80 macrophage marker. The
sections were observed under Zeiss LSM 710 NLO confocal microscope for DiI and
FITC localizations.
In vivo therapeutic efficacy of fusogenic NPs. Eight-week-old male Balb/C mice
were intratracheally infected as described. Twenty-four hours post infection,
infected mice were intravenously injected with 100 μl of PBS or siIrf5-loaded
fusogenic pSiNPs conjugated with CRV at 23.2 µmol/kg lipid, corresponding to 69
µg/kg siRNA, and 0.3 mg/kg pSi in 100 μl PBS. PBS-injected mouse was collected
for the lungs ad mortem (24 h post injection), whereas nanoformulation-injected
mouse was killed and collected for the lungs 3 days post injection. In addition,
lungs from healthy mouse and infected mouse with no injection, at 24 h post
infection, were collected. All organs were immediately fixed in 4% PFA to be sent to
the UCSD histology core for paraffinization, sectioning, and H&E staining. The
stained sections were histopathologically evaluated by Dr Kent Osborn (Associate
Director, Animal Care Program, UCSD).
To confirm clearance of bacteria from lungs, the number of CFUs of S. aureus
was determined from titering of lung homogenates. Twenty-four hours post
infection, mice were intravenously injected with 100 μl of PBS, NF particles with
siIrf5 and CRV conjugation, fusogenic particles with sham siRNA (siLuc, luciferase
encoding siRNA) conjugated with CRV, or fusogenic particles with siIrf5 and CRV
conjugation at 23.2 µmol/kg lipid, corresponding to 69 µg/kg siRNA, and 0.3 mg/kg
pSi in 100 μl PBS. Healthy mice with no injection were also observed. At days 2, 3,
4, and 8 post infection, mice were killed for lung collection. Due to factors that may
affect the bacteria count on the day of the therapeutics injection, day 1 (i.e.,
variations in before vs. after injection, the number of hours post injection, etc.), we
began the count at day 2. In cases where mice succumbed to infection before the
time points, the lungs were collected ad mortem. The lungs were weighed, gently
washed in PBS, and then homogenized. The homogenates were serially diluted to a
dilution factor of 107, plated on agar-coated petri dishes, and incubated at 37 °C
overnight. The S. aureus colonies were counted n= 4 for each dilution factor and
divided by the lung mass. The average CFU/g was quantified using counts from
four plates at equivalent dilution factors from two mice (n= 4 plates × 2 mice= 8).
Finally, a survival challenge was performed with infected mice, who were
intravenously injected 24 h post infection with the treatment compounds. Each
group had eight mice, which were blindly observed daily for survival. Moribund
mice that showed signs of expiring within 5 h were killed according to the IACUC
guidelines. The resulting data were statistically evaluated using single-way ANOVA
and post hoc comparisons using Tukey’s HSD test at p < 0.05.
In vivo Irf5 knockdown efficiency. Eight-week-old male Balb/C mice were
intratracheally infected as described above. Twenty-four hours post infection,
infected mice were intravenously injected with 100 μl of PBS or siIrf5-loaded
fusogenic and NF-pSiNPs with or without CRV at 23.2 µmol/kg lipid, corre-
sponding to 69 µg/kg siRNA, and 0.3 mg/kg pSi in 100 μl PBS. Twenty-four hours
post injection and circulation, mice were killed for BAL. BAL was performed by
intratracheal instillation of a mouse catheter, with a suture tied around the trachea
to prevent leakage. One milliliter of PBS was injected into the lungs through the
catheter and aspirated back out. The process was repeated three times to collect up
to 2.5 ml of the BAL fluid. Lungs were also collected after completion of the BAL
procedure.
Cells from the BAL fluid were collected by centrifugation at 350 × g for 10 min
at room temperature. The supernatant was removed and the cell pellets were
washed with PBS once by centrifugation at 350 × g for 10 min at room temperature.
Before qRT-PCR processing, the cell pellets were kept dry at − 80 °C. Collected
lungs were weighed and homogenized, 30 mg of the homogenates were isolated for
qRT-PCR processing, and stored at − 80 °C.
The in vivo knockdown of Irf5 was quantified using two-step qRT-PCR (Roche
LightCycler 96). The cell pellets or the lung homogenates were lysed and RNA was
purified using the QIAshredder and RNeasy Mini Kit (Qiagen). cDNA was
transcribed from the purified RNA using the BIORAD iScript cDNA Synthesis Kit
and heat-treated in the Eppendorf Vapo.protect Mastercycler thermal cycler.
cDNA was mixed with Irf5 primers, or the control HPRT primers (Irf5 forward: 5′-
AATACCCCACCACCTTTTGA-3′; Irf5 reverse: 5′-TTGAGATCCGGGTTTGA
GAT-3′; HPRT forward: 5′-GTCAACGGGGGACATAAAAG-3′; HPRT reverse:
5′-CAACAATCAAGACATT-CTTTCCA-3′) and iQ SYBR Green Supermix
according to the manufacturer’s instructions. qRT-PCR analysis was performed in
the BIORAD 96-well white Multiplate PCR Plates using the Roche LightCycler 96.
The quantification was performed at n= 6 and in RNAse- and DNAse-free laminar
flow hood dedicated to RNA work. Relative knockdown was statistically evaluated
using one-way ANOVA with Tukey’s HSD post hoc analysis.
Data availability. The data that support the findings of this study are available
from the corresponding author upon request.
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